NurExone Biologic
BNEI-BRAK, Israel · Biotechnology
NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.
Key facts
- Headquarters
- BNEI-BRAK, Israel
- Employees
- 25
- Industries
- Biotechnology
- Status
- Private
- Website
- nurexone.com
- Company page
Recent activity at NurExone Biologic
- : NurExone Biologic Enters 5-Year Manufacturing Partnership with Made Scientific for Bone-Marrow-Derived Exosomes.
- : NurExone Biologic
- : NurExone Biologic
- : NurExone Biologic
- : NurExone Biologic
- : NurExone Biologic
- : NurExone Biologic
- : NurExone Biologic Inc. Announces Acquisition of Master Cell Bank to Enhance Exosome-Based Therapies.
- : NurExone Announces Transfer of Manufacturing of ExoPTEN Drug to GMP Manufacturer
- : NurExone Biologic
NurExone Biologic funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Seed | $450K |
| Jul 2026 | Seed | $442K |
| Mar 2026 | Seed | $280K |
| Aug 2025 | Venture | $148K |
| Apr 2025 | Venture | $1.6M |
Leadership
- Limor Chen, Head of Scientific Collaborations & External Partnerships
- Oded Orgil, Director
- Yoram Drucker, Director
- Gadi Riesenfeld, Director
- Eran Ovadya, Executive Officer
- Lior Shaltiel, Director
- Oded Orgil, Director
- Yoram Drucker, Director
- Gadi Riesenfeld, Director
- Eran Ovadya, Executive Officer
- Lior Shaltiel, Director
- Oded Orgil, Director
Verified email and direct lines for NurExone Biologic’s decision-makers are on Fundz. See plans
NurExone Biologic in the news
- NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model - GlobeNewswire (Oct 08, 2025)
- A next-generation therapeutic approach for patients after spinal cord injuries - Nature (Oct 11, 2023)
- NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment - BioInformant (Nov 07, 2023)
- NurExone Biologic Inc. (NRX.V) Company Profile & Facts - Yahoo! Finance Canada (Jul 23, 2022)
- NurExone Reports New Preclinical Tissue-Analysis Data - GlobeNewswire (Aug 14, 2026)
- NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference - The Manila Times (Aug 29, 2026)
- Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico - The Manila Times (Jun 25, 2026)
- NurExone Biologic Announces Advancements in Extracellular - GlobeNewswire (Jul 20, 2023)
Companies similar to NurExone Biologic
- Tenpoint Therapeutics · Biotechnology
- Sonavex · Biotechnology
- ILiAD Biotechnologies · Biotechnology
- Paradigm Biopharmaceuticals · Biotechnology
- Seegnal eHealth Ltd · Biotechnology
About NurExone Biologic: questions and answers
What does NurExone Biologic do?
NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.
Where is NurExone Biologic headquartered?
NurExone Biologic is headquartered in BNEI-BRAK, Israel.
How many employees does NurExone Biologic have?
NurExone Biologic has about 25 employees.
Has NurExone Biologic raised funding?
Yes. Fundz has recorded 5 funding events for NurExone Biologic. The most recent, Seed of $450K, was in Aug 2026.
What is the latest news on NurExone Biologic?
On Aug 22, 2026, NurExone Biologic Enters 5-Year Manufacturing Partnership with Made Scientific for Bone-Marrow-Derived Exosomes.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy